{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:11:25Z","timestamp":1787796685607,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Pegylated asparaginase is now standard in US treatment protocols for acute lymphoblastic leukemia (ALL). However, they are associated with significant side effects, including severe hypertriglyceridemia. In this case series, we report 8 patients with severe (triglyceride &gt;1000\u00a0mg\/dL) hypertriglyceridemia after receiving long-acting asparaginase for ALL and describe their clinical course. The 8 patients included 3 females and 5 males (aged 2 to 14\u00a0y; median=12\u00a0y); 7 were Hispanic and 1 was Middle Eastern. The median time from dose to peak hypertriglyceridemia was 17 days and to resolution was 25 days. Presentations included isolated hypertriglyceridemia, pseudohyponatremia, hypoglycemia, and lipemia interfering with complete blood count results. Median length of hospitalization was 3.5 days. Management included hydration, a low-fat diet, omega-3 supplements, fenofibrates, statins, and levocarnitine. An insulin drip was used in 2 patients in the intensive care unit. Asparaginase treatment continued per protocol after triglyceride levels were &lt;1000\u00a0mg\/dL. In conclusion, severe hypertriglyceridemia can occur after long-acting asparaginase and is typically asymptomatic and transient, not requiring a pause or modification in treatment. We recommend monitoring for hypertriglyceridemia closely in patients with risk factors who are resuming long-acting asparaginase therapy after triglyceride levels fall &lt;1000\u00a0mg\/dL.<\/jats:p>","DOI":"10.1097\/mph.0000000000003077","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:00:23Z","timestamp":1750856423000},"page":"e215-e221","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Severe Hypertriglyceridemia Secondary to Long-acting Asparaginase in Pediatric Patients With Acute Lymphoblastic Leukemia"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-7516","authenticated-orcid":false,"given":"Amr","family":"Elgehiny","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McCall","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Nunez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam B.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Castellanos","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Funck","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehla","family":"Razvi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00280-016-3236-y","article-title":"Asparaginase pharmacology: challenges still to be faced","volume":"79","author":"Lanvers-Kaminsky","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nyas.12496","article-title":"Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia","volume":"1329","author":"Salzer","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children\u2019s Oncology Group (POG 9404)","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases comparative pharmacology and optimal use in childhood leukemia","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"R6-20260422","first-page":"241","article-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","volume":"1","author":"Avramis","year":"2006","journal-title":"Int J Nanomed"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1080\/10428194.2017.1393672","article-title":"Pegasparaginase silent inactivation during therapy for NK\/T cell lymphoma","volume":"59","author":"Neumann","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1078-0432.CCR-19-2975","article-title":"Space for calaspargase? A new asparaginase for acute lymphoblastic leukemia","volume":"26","author":"Lew","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA approval summary: calaspargase pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults","volume":"26","author":"Li","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1515\/jpem-2023-0122","article-title":"Very severe hypertriglyceridemia complicating pediatric acute lymphoblastic leukemia treatment: a call for management guidelines","volume":"36","author":"Baxter","year":"2023","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"e30683","DOI":"10.1002\/pbc.30683","article-title":"Hyperlipidemia in children and adolescents with acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"70","author":"Laumann","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/08880018.2020.1756999","article-title":"Lipid apheresis to manage severe hypertriglyceridemia during induction therapy in a child with acute lymphoblastic leukemia","volume":"37","author":"Mayerhofer","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00442614","article-title":"The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia","volume":"147","author":"Cremer","year":"1988","journal-title":"Eur J Pediatr"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","article-title":"Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"89","author":"Parsons","year":"1997","journal-title":"Bloody"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.ejca.2014.06.023","article-title":"Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia","volume":"50","author":"Bhojwani","year":"2014","journal-title":"Eur J Cancer"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"e28040","DOI":"10.1002\/pbc.28040","article-title":"Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia","volume":"67","author":"Finch","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.V124.21.2256.2256","article-title":"Toxicity of very prolonged PEGasparaginase and Erwinia asparaginase courses in relation to asparaginase activity levels with a special focus on dyslipidemia","volume":"124","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J Clin Oncol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"pbc.26555","DOI":"10.1002\/pbc.26555","article-title":"Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU","volume":"64","author":"Lebovic","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.3324\/haematol.2016.160507","article-title":"Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia","volume":"102","author":"Mogensen","year":"2017","journal-title":"Haematologica"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/164_2015_1","article-title":"Glucocorticoids and metabolic control","volume":"233","author":"Magomedova","year":"2016","journal-title":"Metabol Control"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"e26559","DOI":"10.1002\/pbc.26559","article-title":"Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents","volume":"64","author":"Persson","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/bjh.17936","article-title":"Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia","volume":"196","author":"Egnell","year":"2022","journal-title":"Br J Haematol"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jacl.2018.05.021","article-title":"Combination therapy of omega-3 fatty acids and acipimox for children with hypertriglyceridemia and acute lymphoblastic leukemia","volume":"12","author":"Salvador","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17425255.2023.2233412","article-title":"Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding","volume":"19","author":"Alqahtani","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2006.07.7792","article-title":"Obesity and outcome in pediatric acute lymphoblastic leukemia","volume":"25","author":"Butturini","year":"2007","journal-title":"J Clin Oncol"},{"key":"R32-20260422","doi-asserted-by":"crossref","first-page":"113000","DOI":"10.1016\/j.biopha.2022.113000","article-title":"Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia","volume":"150","author":"Wu","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R33-20260422","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000524261","article-title":"Prevalence of childhood obesity in the United States in 1999-2018: a 20-year analysis","volume":"15","author":"Tsoi","year":"2022","journal-title":"Obes Facts"},{"key":"R34-20260422","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1080\/10428194.2022.2098288","article-title":"Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population","volume":"63","author":"Lee","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"R35-20260422","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pedneo.2023.06.003","article-title":"Analysis of non-alcoholic fatty liver disease during induction therapy for B-cell precursor acute lymphoblastic leukemia in children and adolescents","volume":"65","author":"Sano","year":"2024","journal-title":"Pediatr Neonatol"},{"key":"R36-20260422","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/jhm.995","article-title":"Management of severe hypertriglyceridemia in the hospital: a review","volume":"7","author":"Schaefer","year":"2012","journal-title":"J Hosp Med"},{"key":"R37-20260422","doi-asserted-by":"crossref","first-page":"28j","DOI":"10.1016\/S0002-9149(99)00355-0","article-title":"Insulin resistance and lipid metabolism","volume":"84","author":"Howard","year":"1999","journal-title":"Am J Cardiol"},{"key":"R38-20260422","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1080\/10428194.2018.1435873","article-title":"Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature","volume":"59","author":"Schulte","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"R40-20260422","article-title":"Ultra-fast multi-organ proteomics unveils tissue-specific mechanisms of drug efficacy and toxicity","author":"Xiong","year":"2024","journal-title":"bioRxiv"},{"key":"R41-20260422","doi-asserted-by":"crossref","first-page":"117501","DOI":"10.1016\/j.atherosclerosis.2024.117501","article-title":"Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention","volume":"391","author":"Gagnon","year":"2024","journal-title":"Atherosclerosis"},{"key":"R42-20260422","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:01:26Z","timestamp":1776844886000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003077","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"2025-02-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}